These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23295262)

  • 41. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P
    Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
    J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
    Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
    Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B; Kositanont U; Rittayamai N; Niyomthong P; Songserm T; Maranetra KN; Rattanasaengloet K; Nana A
    Hum Vaccin Immunother; 2016 Jul; 12(7):1728-37. PubMed ID: 27153158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP; Li W; Liang XF; Liu Y; Huang XC; Li CG; Li RC; Wang JZ; Wang HQ; Yin WD
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1297-307. PubMed ID: 23134570
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.
    Scheifele DW; McNeil SA; Ward BJ; Dionne M; Cooper C; Coleman B; Loeb M; Rubinstein E; McElhaney J; Hatchette T; Li Y; Montomoli E; Schneeberg A; Bettinger JA; Halperin SA;
    Hum Vaccin Immunother; 2013 Nov; 9(11):2460-73. PubMed ID: 23839537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.
    Seo YB; Lee J; Song JY; Choi HJ; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016; 12(2):478-84. PubMed ID: 26431466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years).
    Duggan ST; Plosker GL
    Drugs Aging; 2010 Jul; 27(7):597-605. PubMed ID: 20583853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.
    Egunsola O; Clement F; Taplin J; Mastikhina L; Li JW; Lorenzetti DL; Dowsett LE; Noseworthy T
    JAMA Netw Open; 2021 Feb; 4(2):e2035693. PubMed ID: 33560425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.
    Coudeville L; Andre P; Bailleux F; Weber F; Plotkin S
    Hum Vaccin; 2010 Oct; 6(10):841-8. PubMed ID: 20930559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
    Madan A; Ferguson M; Rheault P; Seiden D; Toma A; Friel D; Soni J; Li P; Innis BL; Schuind A
    Vaccine; 2017 Apr; 35(15):1865-1872. PubMed ID: 28302407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.
    Chuaychoo B; Kositanont U; Niyomthong P; Rittayamai N; Srisuma S; Rattanasaengloet K; Wongsrisakunkaew W; Thongam J; Songserm T
    Hum Vaccin Immunother; 2020 Jun; 16(6):1371-1379. PubMed ID: 31770051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial.
    Chan TC; Hung IF; Chan KH; Li CP; Li PT; Luk JK; Chu LW; Chan FH
    J Am Med Dir Assoc; 2014 Aug; 15(8):607.e5-12. PubMed ID: 24957950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.